A Multicenter, Phase 3, Open-Label Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mirikizumab in Participants 2 Years to Less Than 18 Years of Age With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 09 Jun 2026
At a glance
- Drugs Mirikizumab (Primary) ; Mirikizumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms SHINE-2
- Sponsors Eli Lilly and Company
Most Recent Events
- 03 Jun 2026 Status changed from recruiting to completed.
- 24 Apr 2026 The study has been completed in Poland, Italy, Portugal, Belgium, Germany, Netherlands and France..
- 18 Apr 2025 Planned End Date changed from 1 Mar 2027 to 1 Aug 2026.